Carle F Carle: Influence Statistics

Carle F Carle

Carle F Carle

CHU de Toulouse, Dermatologie, Toulouse, France | Department of Dermatology, Medical University of Toulouse, Toulouse, France | Department of Dermatology, Toulouse University ...

Carle F Carle: Expert Impact

Concepts for which Carle F Carle has direct influence: Atopic dermatitis , Psoriatic arthritis , Psoriasis patients , Pimecrolimus cream , Severe psoriasis , Plaque psoriasis , Patients psoriasis .

Carle F Carle: KOL impact

Concepts related to the work of other authors for which for which Carle F Carle has influence: Atopic dermatitis , Psoriatic arthritis , Patients psoriasis , Pimecrolimus cream , Monoclonal antibodies , Quality life , Toxic epidermal necrolysis .

KOL Resume for Carle F Carle

Year
2022

CHU de Toulouse, Dermatologie, Toulouse, France

.

2021

Dermatology Department, Paul Sabatier University, University Hospital of Toulouse, Toulouse, France.

UDEAR, INSERM, Université Toulouse III, U1056, CHU de Purpan, place du Dr Baylac TSA40031, 31059 Toulouse cedex 9, France

2020

Department of Dermatology, Mastocytosis National Reference Center (CEREMAST), Toulouse University Hospital, Toulouse, France

Dermatologie, hôpital Larrey

2019

Université Paul Sabatier, CHU Toulouse, Dermatologie, Toulouse, France

2018

Toulouse University and CHU Hôpital Larrey, Toulouse, France

2017

Department of dermatology, Rangueil-Larrey hospital, Paul-Sabatier university, 31059 Toulouse, France.

Paul Sabatier University University Hospitals of Toulouse Toulouse France

Dermatologie, Toulouse

Prominent publications by Carle F Carle

KOL-Index: 28325 . BACKGROUND: Ixekizumab is a humanised monoclonal antibody against the proinflammatory cytokine interleukin 17A. We report two studies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specifically targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis. METHODS: In two prospective, double-blind, multicentre, phase 3 studies ...
Known for Placebo Etanercept | Patients Ixekizumab | 2 Weeks | Nonsteroidal Antibodies
KOL-Index: 23063 . OBJECTIVE: Pimecrolimus cream (SDZ ASM 981), a nonsteroid inhibitor of inflammatory cytokines, is effective in atopic dermatitis (AD). We assessed whether early treatment of AD signs/symptoms with pimecrolimus could influence long-term outcome by preventing disease flares. METHODS: Early intervention with pimecrolimus was compared with a conventional AD treatment strategy (ie, emollients ...
Known for Patients Pimecrolimus | 12 Months | Atopic Dermatitis | Incidence Adverse Events
KOL-Index: 20967 . BACKGROUND: Early clinical studies suggested that the anti-interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis. METHODS: In two phase 3 studies (AMAGINE-2 and AMAGINE-3), patients with moderate-to-severe psoriasis were randomly assigned to receive brodalumab (210 mg or 140 mg every 2 weeks), ustekinumab (45 mg for patients with a body weight ...
Known for Brodalumab Patients | Placebo Week | Phase 3 Studies | Ustekinumab Psoriasis
KOL-Index: 18956 . BACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses associated with psoriasis. OBJECTIVES: ESTEEM 2 evaluated the efficacy and safety of apremilast 30 mg twice daily for moderate-to-severe plaque psoriasis. METHODS: This phase III, double-blind, placebo-controlled trial randomized adults to apremilast or placebo (2 : 1). At week 16, placebo patients ...
Known for 52 Weeks | 4 Inhibitor | Phase Iii | Oral Phosphodiesterase
KOL-Index: 18853 . Previous epidemiological studies have demonstrated a high prevalence of cardiovascular (CV) risk factors in psoriasis patients, including metabolic syndrome, cigarette smoking, obesity, hypertension, diabetes mellitus, insulin resistance and dyslipidaemia. An increase in CV morbidity and mortality attributable to psoriasis is still under question. PRIMARY OBJECTIVE: to assess CV morbidity ...
Known for Psoriatic Arthritis | Cardiovascular Morbidity | Psoriasis Mortality | Risk Stroke
KOL-Index: 17976 . BACKGROUND: Psoriasis is an autoimmune disease that affects approximately 100 million people worldwide, and is a disease that can be ameliorated by anti-cytokine treatment. We aimed to compare the efficacy and safety of risankizumab with adalimumab in patients with moderate-to-severe plaque psoriasis. METHODS: IMMvent was a phase 3, randomised, double-blind, active-comparator-controlled ...
Known for Patients Risankizumab | Plaque Psoriasis | Pasi Week | Phase 3
KOL-Index: 16059 . BACKGROUND: The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with monoclonal antibodies, such as dupilumab, that block interleukin-4 receptors are limited. METHODS: In a phase 3, double-blind trial, we randomly assigned ...
Known for Atopic Dermatitis | Abrocitinib Dupilumab | Placebo Iga Response | 200 100
KOL-Index: 15951 . BACKGROUND: The interleukin-17 cytokine family plays a central role in psoriasis pathogenesis. OBJECTIVES: To evaluate the efficacy and safety of brodalumab, a human anti-interleukin-17 receptor antibody, in treating patients with moderate-to-severe plaque psoriasis. METHODS: In this phase III, double-blind, placebo-controlled study (NCT01708590; AMAGINE-1), adult patients in the U.S.A., ...
Known for Brodalumab Patients | Monoclonal Antibodies | 210 Q2w | Severe Plaque
KOL-Index: 15722 . BACKGROUND: It has been shown that the interleukin (IL)-23/IL-17 axis is critical in the pathogenesis of psoriasis. OBJECTIVES: To present the primary end point (week 12) and safety and efficacy data up to week 24 from a head-to-head trial (IXORA-S) of the IL-17A inhibitor ixekizumab (IXE) vs. the IL-12/23 inhibitor ustekinumab (UST). METHODS: Randomized patients received IXE (160-mg ...
Known for Pasi Week | Moderate‐to‐severe Psoriasis | Ixe Ust | Primary Point
KOL-Index: 15089 . BACKGROUND: Oral 8-methoxypsoralen-UV-A (PUVA) and narrowband UV-B (NB-UVB or UVB TL-01) are effective and widely used treatments for chronic plaque psoriasis. Although the role of PUVA therapy in skin carcinogenesis in humans with psoriasis has been clearly demonstrated, there is still controversy regarding the risk of skin cancer with NB-UVB. Furthermore, there is no clear evidence about ...
Known for Chronic Plaque Psoriasis | Skin Cancer | Carcinogenic Risk | Puva Therapy
KOL-Index: 14746 . BACKGROUND: Patients with plaque psoriasis treated with biologic therapies need more efficacious, safe and convenient treatments to improve quality of life. Risankizumab and secukinumab inhibit interleukin-23 and interleukin-17A, respectively, and are effective in adult patients with moderate-to-severe plaque psoriasis but have different dosing regimens. OBJECTIVES: To compare directly the ...
Known for Plaque Psoriasis | Risankizumab Secukinumab | Monoclonal Antibodies | Patients Pasi
KOL-Index: 14588 . BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor that is being investigated for psoriasis. Psoriasis impacts on physical and psychological well-being; improvements in health-related quality of life (HRQoL) with etanercept in psoriasis are well documented. OBJECTIVE: To evaluate HRQoL with tofacitinib, vs. placebo or etanercept, in the Phase 3, randomized, placebo-controlled, ...
Known for Tofacitinib Placebo | 10 Bid | Phase 3 Study | Plaque Psoriasis
KOL-Index: 14536 . BACKGROUND: Fixed combination calcipotriol 50 μg/g (Cal) plus betamethasone 0.5 mg/g (BD) foam has been developed as a new treatment option for patients with psoriasis. METHODS: The randomized, parallel-group, investigator-blinded Phase III, 12-week PSO-ABLE study compared the efficacy and safety of Cal/BD foam with Cal/BD gel. Patients aged ≥18 years with mild-to-severe psoriasis were ...
Known for Cal Gel | Betamethasone Dipropionate | Aerosol Foam | Psoriasis Vulgaris
KOL-Index: 14256 . BACKGROUND: High doses of corticosteroids are considered the standard treatment for pemphigus. Because long-term corticosteroid treatment can cause severe and even life-threatening side-effects in patients with this disease, we assessed whether first-line use of rituximab as adjuvant therapy could improve the proportion of patients achieving complete remission off-therapy, compared with ...
Known for Rituximab Prednisone | Patients Pemphigus | Ritux 3 | Complete Remission
KOL-Index: 13601 . BACKGROUND: Available literature on psoriasis and psoriatic arthritis (PsA) demonstrates a tremendous burden of disease and suggests underdiagnosis and undertreatment. OBJECTIVE: To obtain real-world physician perspectives on the impact of psoriasis and PsA and its treatment on patients' daily lives, including perceptions of, and satisfaction with, current therapies. METHODS: The ...
Known for Psoriatic Arthritis | Patients Psoriasis | Dermatologists Rheumatologists | Cutaneous Administration

Key People For Atopic Dermatitis

Top KOLs in the world
#1
Donald Y M Leung
atopic dermatitis eczema herpeticum food allergy
#2
Thomas RM Bieber
atopic dermatitis dendritic cells lupus erythematosus
#3
Jon M Hanifin
atopic dermatitis eczema herpeticum histamine release
#4
Mark Boguniewicz
atopic dermatitis eczema herpeticum tacrolimus ointment
#5
Hywel C G Williams
atopic eczema cochrane skin basal cell carcinoma
#6
Johnannes Ring
atopic eczema west germany histamine release

CHU de Toulouse, Dermatologie, Toulouse, France | Department of Dermatology, Medical University of Toulouse, Toulouse, France | Department of Dermatology, Toulouse University Hospital, Toulouse, France | . paul.c@chu-toulouse.fr. | Dermatologie, CHU